Dr. Divakaran is developing novel induced-proximity-based therapeutic modalities for targeted editing of the epigenome to silence the expression of common cancer-causing genes.
published research
Hong SH, Divakaran A, Osa A, Huang OW, Wertz IE, Nomura DK. Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation. ACS Chem Biol. 2024.
Divakaran A, Harki DA, Pomerantz WCK. Recent progress and structural analyses of domain-selective BET inhibitors. Med Res Rev. 2023.